Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy

M. B. Kleinman, E. L. Wiley, M. Guo, A. W. Rademaker, M. Villa, M. S. Tallman, S. B. Newman, L. I. Gordon, J. N. Winter

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mobilized peripheral blood progenitor cells (PBPC) from 30 patients with advanced breast cancer were studied for the presence of tumor cell contamination using a highly sensitive immunohistochemical technique with the capacity to detect one tumor cell in one million mononuclear cells. Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide. The overall incidence of tumor cell contamination was 23%, occurring in PBPC specimens from seven of 30 patients. All four cases in which tumor cells were detected after mobilization with cytokine alone also had tumor cells detected in PBPCs collected following chemotherapy and G-CSF. There were three cases in which malignant contamination was detected only in the specimens collected after cyclophosphamide. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance. This trend suggests that collection of PBPC during cytokine-stimulated recovery from myelosuppressive chemotherapy may be associated with a greater risk of contamination with malignant cells than apheresis during mobilization with cytokines in the steady state.

Original languageEnglish
Pages (from-to)1297-1301
Number of pages5
JournalBone Marrow Transplantation
Volume23
Issue number12
StatePublished - Jun 2 1999
Externally publishedYes

Fingerprint

Blood Cells
Stem Cells
Breast Neoplasms
Cytokines
Drug Therapy
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Neoplasms
Blood Component Removal
Granulocyte-Macrophage Colony-Stimulating Factor
Incidence

Keywords

  • Apheresis
  • Breast cancer
  • Minimal residual disease

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. / Kleinman, M. B.; Wiley, E. L.; Guo, M.; Rademaker, A. W.; Villa, M.; Tallman, M. S.; Newman, S. B.; Gordon, L. I.; Winter, J. N.

In: Bone Marrow Transplantation, Vol. 23, No. 12, 02.06.1999, p. 1297-1301.

Research output: Contribution to journalArticle

Kleinman, MB, Wiley, EL, Guo, M, Rademaker, AW, Villa, M, Tallman, MS, Newman, SB, Gordon, LI & Winter, JN 1999, 'Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy', Bone Marrow Transplantation, vol. 23, no. 12, pp. 1297-1301.
Kleinman, M. B. ; Wiley, E. L. ; Guo, M. ; Rademaker, A. W. ; Villa, M. ; Tallman, M. S. ; Newman, S. B. ; Gordon, L. I. ; Winter, J. N. / Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. In: Bone Marrow Transplantation. 1999 ; Vol. 23, No. 12. pp. 1297-1301.
@article{cad00960bab4441a956fc9ecf50c903f,
title = "Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy",
abstract = "Mobilized peripheral blood progenitor cells (PBPC) from 30 patients with advanced breast cancer were studied for the presence of tumor cell contamination using a highly sensitive immunohistochemical technique with the capacity to detect one tumor cell in one million mononuclear cells. Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide. The overall incidence of tumor cell contamination was 23{\%}, occurring in PBPC specimens from seven of 30 patients. All four cases in which tumor cells were detected after mobilization with cytokine alone also had tumor cells detected in PBPCs collected following chemotherapy and G-CSF. There were three cases in which malignant contamination was detected only in the specimens collected after cyclophosphamide. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13{\%} vs 23{\%}; P = 0.08), although this did not reach statistical significance. This trend suggests that collection of PBPC during cytokine-stimulated recovery from myelosuppressive chemotherapy may be associated with a greater risk of contamination with malignant cells than apheresis during mobilization with cytokines in the steady state.",
keywords = "Apheresis, Breast cancer, Minimal residual disease",
author = "Kleinman, {M. B.} and Wiley, {E. L.} and M. Guo and Rademaker, {A. W.} and M. Villa and Tallman, {M. S.} and Newman, {S. B.} and Gordon, {L. I.} and Winter, {J. N.}",
year = "1999",
month = "6",
day = "2",
language = "English",
volume = "23",
pages = "1297--1301",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy

AU - Kleinman, M. B.

AU - Wiley, E. L.

AU - Guo, M.

AU - Rademaker, A. W.

AU - Villa, M.

AU - Tallman, M. S.

AU - Newman, S. B.

AU - Gordon, L. I.

AU - Winter, J. N.

PY - 1999/6/2

Y1 - 1999/6/2

N2 - Mobilized peripheral blood progenitor cells (PBPC) from 30 patients with advanced breast cancer were studied for the presence of tumor cell contamination using a highly sensitive immunohistochemical technique with the capacity to detect one tumor cell in one million mononuclear cells. Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide. The overall incidence of tumor cell contamination was 23%, occurring in PBPC specimens from seven of 30 patients. All four cases in which tumor cells were detected after mobilization with cytokine alone also had tumor cells detected in PBPCs collected following chemotherapy and G-CSF. There were three cases in which malignant contamination was detected only in the specimens collected after cyclophosphamide. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance. This trend suggests that collection of PBPC during cytokine-stimulated recovery from myelosuppressive chemotherapy may be associated with a greater risk of contamination with malignant cells than apheresis during mobilization with cytokines in the steady state.

AB - Mobilized peripheral blood progenitor cells (PBPC) from 30 patients with advanced breast cancer were studied for the presence of tumor cell contamination using a highly sensitive immunohistochemical technique with the capacity to detect one tumor cell in one million mononuclear cells. Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide. The overall incidence of tumor cell contamination was 23%, occurring in PBPC specimens from seven of 30 patients. All four cases in which tumor cells were detected after mobilization with cytokine alone also had tumor cells detected in PBPCs collected following chemotherapy and G-CSF. There were three cases in which malignant contamination was detected only in the specimens collected after cyclophosphamide. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance. This trend suggests that collection of PBPC during cytokine-stimulated recovery from myelosuppressive chemotherapy may be associated with a greater risk of contamination with malignant cells than apheresis during mobilization with cytokines in the steady state.

KW - Apheresis

KW - Breast cancer

KW - Minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=0033516272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033516272&partnerID=8YFLogxK

M3 - Article

C2 - 10414919

AN - SCOPUS:0033516272

VL - 23

SP - 1297

EP - 1301

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -